Successful Phase 3 study results for Ocular's Axpaxli wet AMD drug
Axpaxli

Successful Phase 3 study results for Ocular's Axpaxli wet AMD drug

Ocular Therpeutix announced successful results of their experimental drug Axpaxli in treating wet age-related macular degeneration.  
New AMD drug completes Phase 2 trial
EyePoint

New AMD drug completes Phase 2 trial

EyePoint Pharmaceuticals announced the completion of the Phase 2 trial of their new experimental drug, vorolanib, for the treatment of wet age-related macular degeneration.
Regeneron receives FDA approval for EYLEA HD
diabetic macular edema

Regeneron receives FDA approval for EYLEA HD

The Food and Drug Administraton (FDA) gave approval after two active-controlled, double-masked pivotal trials, which compared EYLEA HD to EYLEA over a 48 week period.